Goldman Sachs
BXRX

Goldman Sachs’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Goldman Sachs’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-108
Closed -$115K – 6685
2021
Q2 		$115K Buy
+108
New +$141K ﹤0.01% 5911
2020
Q3 		– Sell
-7
Closed -$42K – 5620
2020
Q2 		$42K Buy
+7
New +$33.6K ﹤0.01% 5079

Other funds holding BXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Goldman Sachs's BXRX Position: Q3 2021 in Review

Goldman Sachs sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q3 2021, closing a stake of 108 shares — an estimated $115K sold.

Goldman Sachs first reported a position in BXRX in Q2 2020 and held it in 2 quarters. The position peaked at $115K in Q2 2021. 26 funds tracked by Wall St. Rank hold BXRX as of Q3 2021.

  • Goldman Sachs reported no remaining Baudax Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Goldman Sachs sold 108 Baudax Bio, Inc. Common Stock shares in Q3 2021, an estimated $115K.
  • Goldman Sachs first reported a position in Baudax Bio, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Goldman Sachs's Baudax Bio, Inc. Common Stock position peaked at $115K in Q2 2021.
  • 26 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.